Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
Feature|Videos|December 18, 2025 (Updated: January 14, 2026)

Inside Codexis: Redefining Pharma Biocatalysis

Mandy Vink, VP of Business Development at Codexis, explains how the company leverages over 20 years of expertise in small molecule APIs to advance biocatalysis across pharma.

Key Objectives

  • Understand how Codexis leverages over two decades of experience with small-molecule APIs to support large pharma partners
  • Learn more about the current trends in small molecule APIs
  • Learn more about the current trends in adopting biocatalysis

Codexis leverages directed evolution and computational biology to develop powerful, sustainable biocatalysts for manufacturing small molecule APIs, a technology critical to partners worldwide and used in drugs like Paxlovid. Mandy Vink, VP of Business Development at Codexis, explores market trends, Codexis’ position in the industry and its collaborations, and what currently drives adoption among innovators and CDMOs.


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.